Lead carbonates: Human health tier II assessment

12 September 2013

- Chemicals in this assessment
- Preface
- Grouping Rationale
- Import, Manufacture and Use
- Restrictions
- Existing Worker Health and Safety Controls
- Health Hazard Information
- Risk Characterisation
- NICNAS Recommendation
- References

Chemicals in this assessment

<table>
<thead>
<tr>
<th>Chemical Name in the Inventory</th>
<th>CAS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbonic acid, lead(2+) salt (1:1)</td>
<td>598-63-0</td>
</tr>
<tr>
<td>Lead, bis(carbonato(2-))dihydroxytri-</td>
<td>1319-46-6</td>
</tr>
</tbody>
</table>

Preface

This assessment was carried out by staff of the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) using the Inventory Multi-tiered Assessment and Prioritisation (IMAP) framework.

The IMAP framework addresses the human health and environmental impacts of previously unassessed industrial chemicals listed on the Australian Inventory of Chemical Substances (the Inventory).

The framework was developed with significant input from stakeholders and provides a more rapid, flexible and transparent approach for the assessment of chemicals listed on the Inventory.

Stage One of the implementation of this framework, which lasted four years from 1 July 2012, examined 3000 chemicals meeting characteristics identified by stakeholders as needing priority assessment. This included chemicals for which NICNAS already held exposure information, chemicals identified as a concern or for which regulatory action had been taken overseas, and chemicals detected in international studies analysing chemicals present in babies’ umbilical cord blood.

Stage Two of IMAP began in July 2016. We are continuing to assess chemicals on the Inventory, including chemicals identified as a concern for which action has been taken overseas and chemicals that can be rapidly identified and assessed by using Stage One information. We are also continuing to publish information for chemicals on the Inventory that pose a low risk to human health or the environment or both. This work provides efficiencies and enables us to identify higher risk chemicals requiring assessment.
The IMAP framework is a science and risk-based model designed to align the assessment effort with the human health and environmental impacts of chemicals. It has three tiers of assessment, with the assessment effort increasing with each tier. The Tier I assessment is a high throughput approach using tabulated electronic data. The Tier II assessment is an evaluation of risk on a substance-by-substance or chemical category-by-category basis. Tier III assessments are conducted to address specific concerns that could not be resolved during the Tier II assessment.

These assessments are carried out by staff employed by the Australian Government Department of Health and the Australian Government Department of the Environment and Energy. The human health and environment risk assessments are conducted and published separately, using information available at the time, and may be undertaken at different tiers.

This chemical or group of chemicals are being assessed at Tier II because the Tier I assessment indicated that it needed further investigation.

For more detail on this program please visit: [www.nicnas.gov.au](http://www.nicnas.gov.au)

Disclaimer

NICNAS has made every effort to assure the quality of information available in this report. However, before relying on it for a specific purpose, users should obtain advice relevant to their particular circumstances. This report has been prepared by NICNAS using a range of sources, including information from databases maintained by third parties, which include data supplied by industry. NICNAS has not verified and cannot guarantee the correctness of all information obtained from those databases. Reproduction or further distribution of this information may be subject to copyright protection. Use of this information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner. NICNAS does not take any responsibility whatsoever for any copyright or other infringements that may be caused by using this information.

ACRONYMS & ABBREVIATIONS

Grouping Rationale

This group of two chemical compounds consists of lead salts of carbonic acid. These compounds have been included in this group due to the expectation that the physico-chemical properties will not vary greatly, leading to the compounds within this group having related end uses. The lead compounds with an unspecified oxidation state will predominantly contain lead in the +2 oxidation state. In addition, information outlined in the Organisation for Economic Co-operation and Development's (OECD) guideline on Grouping of Chemicals (OECD, 2007) provided guidance on the grouping of these chemicals based on physico-chemical or toxicological criteria.

Import, Manufacture and Use

Australian

No specific Australian use, import, or manufacturing information has been identified.

International

The following international uses for the group have been identified through European Union Registration, Evaluation and Authorisation of Chemicals (EU REACH) dossiers; the Organisation for Economic Cooperation and Development Screening information data set International Assessment Report (OECD SIAR); Galleria Chemica; Substances and Preparations in the Nordic countries (SPIN) database; the European Commission Cosmetic Ingredients and Substances (CosIng) database; United States (US) Personal Care Product Council International Nomenclature of Cosmetic Ingredients (INCI) Dictionary; and eChemPortal: OECD High Production Volume chemical program (OECD HPV), the US Environmental Protection Agency’s Aggregated Computer Toxicology Resource (ACToR), and the US National Library of Medicine’s Hazardous Substances Data Bank (HSDB).

Domestic uses including:
Commercial uses including:

- as a process regulator, e.g. a catalyst in the curing of silicone resins.

Site-limited uses including:

- as a component in lubricating greases;
- as a heat stabiliser for polyvinyl chloride polymers.
- in metallurgy, e.g. bearing metals, brass, aluminium and steel used in the automotive industry; and
- as an electroplating agent.

**Restrictions**

**Australian**

Lead and lead compounds are listed in the Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP, 2012)) in:

**Appendix I, Uniform Paint Standard**

Lead compounds are not permitted to be used in domestic or industrial paints at > 0.1 %. The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

**Appendix C**

Lead compounds in paints, tinters, inks or ink additives except in preparations containing = 0.1 % of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.

Appendix C substances, other than those included in Schedule 9, are considered of such danger to health as to warrant prohibition of sale, supply and use. These substances are poisons prohibited from sale, supply or use because of their known potential for harm to human and/or animal health.

**Schedule 6**

Lead compounds unless specified in Appendix C or:

(a) when included in Schedule 4 or 5;

(b) in paints, tinters, inks or ink additives;

(c) in preparations for cosmetic use containing 100 mg/kg or less of lead;

(d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or

(e) in ceramic glazes when labelled with the warning statement: CAUTION - Harmful if swallowed. Do not use on surfaces which contact food or drink. Written in letters not less than 1.5 mm in height.

Schedule 6 substances are considered to have moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

**Schedule 5**
Lead compounds in preparations for use as hair cosmetics, unless specified in Appendix C.

Schedule 5 substances are considered to have low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

**International**

The risk of exposure to lead and lead compounds has been recognised internationally, which has resulted in broad restrictions regarding occupational and public exposure.

**Cosmetics**

Lead compounds appear on the following:

- Health Canada List of Prohibited and Restricted Cosmetic Ingredients (The "Hotlist").
- The EU Cosmetic Directive 76/768/EEC Annex II: List of Substances which must not form part of the Composition of Cosmetic Products.
- The New Zealand Cosmetic Products Group Standard - Schedule 4: Components Cosmetic Products Must Not Contain.
- The Thailand Cosmetic Act - Prohibited Substances.

**Existing Worker Health and Safety Controls**

**Hazard Classification**

The members of this group are not individually listed in the Hazardous Substances Information System (HSIS) and therefore, by default, are covered by the generic 'lead and lead compounds' classification as hazardous with the following risk phrases for human health (Safe Work Australia):

- Repr. Cat. 1; R61 (Reproductive toxicity - may cause harm to the unborn child)
- Repr. Cat. 3; R62 (Reproductive toxicity - possible risk of impaired fertility)
- Xn; R20/R22 (Harmful by inhalation and if swallowed)
- Xn; R33 (Danger of cumulative effects)

**Exposure Standards**

**Australian**

Lead, inorganic dusts and fumes (as lead) have the following exposure standards reported in HSIS (Safe Work Australia). These exposure standards apply to the lead compounds in this assessment:

- Time Weighted Average (TWA): 0.15 mg/m³ for lead compounds (as lead).
- Short-Term Exposure Limits (STEL): No specific exposure standards are available.

**International**

For lead compounds in general, the following exposure limits were identified:
TWA: 0.20 mg/m³ [Thailand, USA (Idaho)]

TWA: 0.15 mg/m³ [Argentina, Canada (Northwest Territories, Yukon), Egypt, European Union, Gibraltar, Hungary, India, Malta, Mexico, Singapore, Slovak Republic, Turkey]

TWA: 0.12 mg/m³ [Chile]

TWA: 0.10 mg/m³ [Austria (Maximum Allowable Concentration (MAK)), New Zealand, Republic of South Africa, Sweden]

TWA: 0.05 mg/m³ [Bulgaria, Canada (Alberta, British Columbia, Prince Edward Island, Nova Scotia, Ontario, Saskatchewan), China (Hong Kong), Italy, Korea (South), Malaysia, Nicaragua, Norway, Peru, Poland, New Zealand, USA (Hawaii, Michigan, North Carolina, Oregon, Washington, Wyoming)]

STEL: 0.60 mg/m³ [Hungary]

STEL: 0.45 mg/m³ [Argentina, Canada (Northwest Territories, Yukon), Egypt]

STEL: 0.40 mg/m³ [Austria MAK]

STEL: 0.15 mg/m³ [Canada (Ontario, Saskatchewan)]

Health Hazard Information

The main concern regarding effects on human health is expected to be driven by the lead component (cation) of these compounds. The component anion for each chemical in this group is the carbonate ion; carbonates have been assessed by NICNAS and are not considered to contribute to the final recommendation (NICNAS a; NICNAS b) as effects are not expected to be observed at levels that are reasonably achievable given the toxicity of the lead component. While limited data are available on these specific chemicals, data sources for determining the hazard of the lead cation include animal studies on well characterised organic and inorganic lead compounds, and a large amount of literature on observations in humans.

Toxicokinetics

Inorganic lead compounds can be absorbed orally, dermally or via inhalation (NICNAS, 2007).

When ingested, the absorption of inorganic lead compounds in the human gastrointestinal tract is influenced by different factors, the most significant being age. Children (up to the age of eight) are estimated to absorb up to 50 % of the lead dose they ingest while adults would absorb up to 10 % of the dose they ingest. This route of absorption can be dependent on solubility and particle size with smaller particles being absorbed more readily than larger ones.

In an oral repeat dose toxicity study, rats were dosed with 0, 200, 500 or 1000 ppm lead acetate and tested for four, eight or 12 weeks. The blood lead concentration (PbB) level range was 40 - 100 µg/dL and the kidney lead levels were highest at four weeks. For all test groups, the urinary lead excretion was highest at four weeks then decreased with continued exposure to lead (REACH).

In an oral repeat dose toxicity study with SD rats, lead carbonate (CAS No. 598-63-0) was administered via oral gavage to 10 male and 10 female rats five days a week for four weeks. Blood lead levels were tested at two, four and six weeks. The highest lead lead levels were at four weeks (REACH).

If inhaled, the size of lead compound particles can dictate the site of deposition and rate of absorption (NICNAS, 2007).

Absorption via the dermal route is the least efficient (NICNAS, 2007). Less than 0.3 % of lead from lead acetate in cosmetics was absorbed dermally in human male volunteers over a 12 hour period. When lead nitrate was applied to the skin, 30 % of the dose was absorbed. It is not known if the absorption was systemic or confined to the layers of the skin.

Lead stored in bone can be released into the blood after exposure has ceased. Distribution in bone is not uniform and lead has been shown to accumulate in areas that are undergoing active calcification at the time of exposure (NICNAS, 2007). Inorganic lead is distributed in the body independently of the source compound.
and route of exposure. The spatial distribution of lead in bone is similar between children and adults, although adults generally have a higher concentration. In blood, 99% of lead is bound to proteins within erythrocytes (NICNAS, 2007).

Mobilisation of lead from bone increases during pregnancy when maternal bone is catabolised to produce the foetal skeleton. It has been shown that up to 80% of lead in human cord blood comes from maternal bone stores and can be transferred into the foetal skeleton during its formation.

The PbB concentration is a reflection of recent exposure and does not capture the more significant impact and slower elimination kinetics of the chemical in bone (ASTDR, 2007). The accumulation of lead in bone is considered a biomarker for long-term exposure over a lifetime. As a result, the affinity of lead for bone would suggest that lead levels in bone, rather than lead levels in blood, provide more relevant predictive information for some health effects associated with long term exposure.

### Acute Toxicity

#### Oral

The members of this group are not individually listed in HSIS and therefore, by default, are covered by the generic 'lead and lead compounds' hazard classification with the risk phrase 'Harmful if swallowed' (Xn; R22) in HSIS (Safe Work Australia). The available data do not support this classification for the lead compounds in this group, as presented below.

In an animal study using basic lead carbonate (CAS No. 1319-46-6), the rat median lethal dose (LD50) was reported to be >2000 mg/kg bw (REACH). Reported signs of toxicity in rats included raised fur, arched back and slightly decreased motor activities which were observed from approximately four hours to nine days after dosing. No other adverse effects were noted during the observation time.

**Lead carbonate** (CAS No. 598-63-0) is reported to have similar solubility to the other lead compound in this group (Lewis, 1996), therefore, is not expected to exhibit greater toxicity than basic lead carbonate (CAS No. 1319-46-6) via the oral route (i.e. is expected to have a similar oral LD50 of >2000 mg/kg bw).

#### Dermal

While no data are available for the chemicals in this group, several lead compounds (dibasic lead phosphite, lead oxide and dibasic lead phthalate) were reported to exhibit low acute toxicity in animal tests as evidenced by reported LD50s in rats of >2000 mg/kg bw (REACH).

#### Inhalation

The members of this group are not individually listed in HSIS and therefore, by default, are covered by the 'lead and lead compounds' hazard classification with the risk phrase ‘Harmful by inhalation’ (Xn; R20) in HSIS (Safe Work Australia). While no data are available for the chemicals in this group, data available from observations in humans support this generic 'lead and lead compounds' classification.

Although a study using lead oxide reported a median lethal concentration (LC50) of >5.05 mg/L for rats, this evidence is insufficient to warrant removal of the generic classification for the chemicals in this group.

#### Observation in humans

In this section, route specific data are not provided but exposure is reported as absorbed dose. The concentration of lead in the blood is the most commonly reported value. However lead in bone, hair and teeth is also reported in the literature.
Adult Exposure

The majority of the data have been collected from accidental or intentional exposure via ingestion or inhalation, and there are rich data regarding the dose-effect in humans (NICNAS, 2007; ATSDR, 2007). Exposure can cause encephalopathy (the signs of which include: hyperirritability, ataxia, convulsions, stupor and coma) in addition to gastrointestinal effects such as colic (displayed as: abdominal pain, constipation, cramps, nausea, vomiting, anorexia and weight loss) (ATSDR, 2007; WHO, 1995). It was recorded that signs of acute toxicity were observed in adults with a PbB level ranging from 50 - 300 µg/dL. However, that is challenged in a more recent study that only noted signs of encephalopathy in adults with PbB levels greater than 460 µg/dL (NICNAS, 2007; ATSDR, 2007).

Colic is indicative of gastrointestinal impact and is typically displayed as an early effect of exposure to lead (NICNAS, 2007; ATSDR, 2007). Colic has been noted in individuals exposed to high levels of lead and can be evident as a result of occupational exposure where workers generally register PbB levels between 100 – 200 µg/dL, although symptoms have been reported by workers with PbB levels between 40 – 60 µg/dL.

Exposure to lead has been reported to cause proximal renal tubular damage (NICNAS, 2007).

Paediatric Exposure

Data were compiled from a paediatric population regarding the dose-response after acute exposure to lead. Signs of encephalopathy were noted in children with PbB levels between 90 – 800 µg/dL. The mean value reported for PbB levels related to death (327 µg/dL) is similar to that noted for encephalopathy (330 µg/dL).

Gastrointestinal effects (abdominal pain, constipation, cramps, nausea, vomiting, anorexia and weight loss) were reported at PbB levels between 60 – 450 µg/dL. Data collected from additional reports indicate that acute encephalopathy was noted in children with PbB levels of 80 – 100 µg/dL and infants at PbB levels of 74.5 µg/dL (NICNAS, 2007).

In paediatric populations, acute colic has also been reported as an effect of poisoning associated with exposure to lead and is noted to occur when the PbB level is greater than or equal to 60 µg/dL (NICNAS, 2007; ATSDR, 2007). In addition, it has been reported that exposure to lead can inhibit the formation of the haem-containing protein cytochrome P450 (NICNAS, 2007).

Corrosion / Irritation

Skin Irritation

In general, lead compounds were reported to be non-irritants (REACH). No effects were reported in skin irritation assays in rabbits citing OECD TG 404 using dibasic lead phosphate or lead oxide.

Eye Irritation

In general, lead compounds were not reported to be irritating to eyes or having caused serious eye damage (REACH). No effects were reported in eye irritation assays in rabbits citing OECD TG 405 using dibasic lead phosphate or lead oxide.

Observation in humans

No studies were located that recorded skin or eye irritation in humans as a result of exposure to lead compounds.

Sensitisation

Skin Sensitisation
In general, lead compounds were reported to be non-sensitisers (REACH). It was reported that the compounds gave negative results for skin sensitisation in guinea pigs when tested according to OECD TG 406 using dibasic lead phosphite, lead oxide and lead phthalate.

Observation in humans

Although altered immune parameters were described in occupational and paediatric groups that were exposed to lead, there were no reports of skin or respiratory sensitisation to lead in humans (ATSDR, 2007).

Repeated Dose Toxicity

Oral

The compounds in this group are not individually listed in HSIS and therefore, by default, are covered by the generic 'lead and lead compounds' hazard classification with the risk phrase 'Danger of cumulative effects' (R33) in HSIS (Safe Work Australia). The available data support this classification for the lead compounds in this group, as presented below.

In a repeated dose toxicity study with Sprague Dawley (SD) rats, lead carbonate (CAS No. 598-63-0) was administered via oral gavage to 10 male rats at 2000 mg/kg per day for 16 days. Decreased body and organ weight, increased blood lead levels and a marked increase in testicular size, haemorrhaging of the testicles, stomach bloating and an absence of mesenteric fat was noted (REACH).

In an oral repeat dose toxicity study with Wistar rats, lead carbonate (CAS No. 598-63-0) was administered in feed at doses of 1%, 2% and 4% per group for nine weeks. The dosed feed was administered at unspecified intervals. A dose-dependent decrease in body weight was reported across all rat test groups. In addition, it was noted that cerebral mitochondrial cells accumulated lead proportionally to the lead carbonate concentration in food. In vitro trials showed that lead accumulated in mitochondrial cells induced alteration, whereas the in vivo results were ambiguous. Further details were not recorded (REACH).

Dermal

While no data are available for the compounds in this group, no significant adverse effects were reported following repeated dermal exposure to several other lead compounds (REACH).

In a report available on repeat dose toxicity during dermal exposure, rats were exposed to lead oleate, lead acetate and tetraethyl lead for 24 hours. The test groups had lead compounds applied either directly to the skin or to skin that had been mechanically injured. Dermal absorption of lead was shown to occur in all the test groups. However, comparatively greater absorption of lead was reported in the groups where the skin had been mechanically injured.

Inhalation

While no data are available for the compounds in this group, no significant adverse effects were reported following repeated inhalation exposure to lead nitrate (REACH).

Aerosolised lead nitrate was administered to mice (Swiss Webster) via inhalation at 2.5 mg/m³ per day for 14 or 28 days. It was determined, considering total retention of the inhaled lead, that each mouse received a dose of 80 µg/day of lead.

A statistically significant reduction in the relative size of the spleen and thymus in both test groups was reported. Increased lung weight was noted in both test groups and an increase lead concentration was reported in the liver, lung and kidney, although the 28 day group was noted to show a greater concentration than the 14 day group. There were no apparent differences in body weight and food consumption noted for either test group.
Observation in humans

Lead has multiple modes of action in biological systems; as a result, any system or organ in the body can potentially be affected by lead exposure. For the purposes of this report, the effects of lead toxicity on the most sensitive target organs have been identified and summarised (NICNAS, 2007; ATSDR, 2007).

Neurological Effects

Lead encephalopathy is considered the most severe neurological effect of lead exposure in adults. Occupational lead exposure has also been linked to neurotoxicity and studies have shown that the following signs and symptoms have been noted in those recorded to have PbB levels of between 40 – 120 µg/dL: malaise, forgetfulness, irritability, lethargy, headache, fatigue, impotence, decreased libido, dizziness, weakness, paraesthesia, visual motor coordination impairment, cognitive performance impairment, decreased reaction time, mood and coping ability as well as affecting memory.

Haematological Effects

Lead exposure impacts on the haematological system by inhibiting haem synthesis and decreasing the lifespan of erythrocytes, which results in the onset of microcytic and hypochromic anaemia (NICNAS, 2007). It has been estimated that the PbB threshold for a decrease in haemoglobin to be seen in occupationally exposed adults is 50 µg/dL. For children the PbB threshold is estimated to be 40 µg/dL.

Cardiovascular Effects

Studies investigating the effect of PbB on blood pressure in humans are not conclusive (NICNAS, 2007; ATSDR, 2007). The cardiovascular endpoint of concern for humans when exposed to low levels of lead is an increase in systemic blood pressure. Longitudinal occupational studies investigating the possible relationship between low level lead exposure and blood pressure have been undertaken, with mixed results. Subsequently, based on the available literature, it is suggested that a relationship between low level exposure to lead and increased systemic blood pressure cannot be determined (NICNAS, 2007).

Renal Effects

Nephrotoxicity associated with lead is characterised by proximal tubular nephropathy, glomerular sclerosis and interstitial fibrosis. The deterioration in renal function is characterised by enzymuria, proteinuria and an impaired ability to transport organic anions and glucose, in addition to a decreased glomerular filtration rate. Studies summarised in ATSDR (2007) indicate that an increase in nephrotoxicity is proportional to an increase in PbB levels. Effects on glomerular filtration are reported at or below 20 µg/dL, enzymuria and proteinuria are reported at equal to or greater than 30 µg/dL and severe deficits in function and pathological changes are reported in association with PbB levels = 50 µg/dL.

Genotoxicity

Lead compounds are considered genotoxic to mammalian cells.

The genotoxic effects of lead were reviewed and presented by the Agency for Toxic Substances and Disease Registry (ATSDR 2007). The majority of the in vitro point mutation tests in bacteria were negative, while mammalian clastogenicity tests were generally positive.

It was reported that in bacterial reverse mutation assays, lead was negative both with and without metabolic activation (REACH). In vitro chromosomal aberration tests using Chinese hamster ovary (CHO) cells and human lymphocytes were positive without metabolic activation. An in vivo micronucleus assay using human peripheral lymphocytes (from those working with lead compounds) was positive below the maximum tolerated dose.

Carcinogenicity

A review conducted by the International Agency for Research on Cancer (IARC) in 1980, which was updated in 1987 and again in 2006, indicated that there was sufficient evidence in experimental animals for the carcinogenicity of inorganic lead compounds.
A subsequent review by the International Lead Association (LDAI, 2008) concluded that lead carbonate exhibits high bioavailability in animal feeding studies and when tested in vitro via gastric simulation systems. There is consistent evidence from studies in rodents that soluble or bioavailable lead compounds are carcinogenic in animals; notably reproducible renal tumours in male rats following administration of high levels of lead via food or water.

This evidence is sufficient to classify the chemicals in this group as potential carcinogens.

**Reproductive and Developmental Toxicity**

The lead compounds in this group are not individually listed in HSIS. Therefore, by default, they are covered by the generic 'lead and lead compounds' hazard classifications with the risk phrases 'Possible risk of impaired fertility' (R62) and 'May cause harm to the unborn child' (R61) in HSIS (Safe Work Australia). While no data are available for the lead compounds in this group, the available data on other lead compounds support these classifications.

In a reproductive and developmental toxicity screening test in SD rats, lead acetate was administered via drinking water to nine females at 0.6 % weight per volume (w/v) (equivalent to 502 mg/kg bw/day) at gestation days 5–21 (Ronis et al, 1996; LDAI, 2008). A stillbirth rate of 19 % was recorded in the test group compared with a 2 % rate noted in the control group. The dams and offspring had PbB levels >200 µg/dL.

In a subsequent reproductive and developmental toxicity screening test in SD rats, lead acetate was administered via drinking water to 10 females at 0.05 % w/v, eight females at 0.15 % w/v and nine females at 0.45% w/v, during gestation days 5–21 (Ronis et al, 1998). Stillbirth rates of 3(±3), 10(±6) and 28(±8) % were recorded for increasing dose groups respectively. This was compared with a 4(±3) % rate noted in the control group. At birth, the male pups had PbB levels of 40(±1), 83(±8) and 120(±120) µg/dL for increasing dose groups respectively, while the female pups had PbB levels of 42(±7), 67(±16) and 197(±82) µg/dL. A developmental LOAEL of 0.05 % (equivalent to 42 mg/kg bw/day) was reported for this study (LDAI, 2008).

**Reproductive toxicity observations in humans**

Recent studies have investigated the effect of lead exposure in occupational groups and general populations living near industrial plants. Although the evidence reported is predominantly qualitative and dose-effect relationships have largely not been established (NICNAS, 2007; WHO, 1995), it has been suggested that moderately high PbB levels in humans could result in spontaneous abortion, pre-term delivery, alterations in sperm and decreased male fertility (ASTDR, 2007).

**Developmental toxicity observations in humans**

Data pertaining to low level exposure to lead contributing to developmental toxicity in infants and young children were recently reviewed. Consensus exists between the reports, which suggest that PbB levels in humans >10 µg/dL can affect paediatric intellectual development (ASTDR, 2007; Donovan, J, 1996).

In addition, data regarding the effects on children of higher levels of lead exposure were reviewed. Although neurobehavioural deficits were reported in children with PbB levels <10 µg/dL, there is uncertainty attached to these estimates of reported effects (ASTDR, 2007). Even so, the US Centers for Disease Control and Prevention (CDC) has a reference level of 5 µg/dL, above which it is recommended that public health action be initiated (CDC).

**Risk Characterisation**

**Critical Health Effects**

The critical health effects for risk characterisation include systemic long-term effects (carcinogenicity, mutagenicity, reproductive toxicity and developmental toxicity). The lead compound may also cause harmful effects following repeated exposure and harmful systemic effects following a single exposure via inhalation.
Public Risk Characterisation

The restrictions on the use of lead and lead compounds in products available to the public in Australia are listed in the Poisons Standard (SUSMP, 2012). These restrictions will prevent risks from domestic use of these compounds.

Given these restrictions, domestic use in paints identified from international sources can be considered to not be relevant to Australia.

Historical use of lead compounds in surface coatings suggests that the potential for the public to be exposed, through flaking paint and during home renovation, still exists. While it is possible that the public will be exposed to lead or lead compounds, the risk can be managed by following appropriate guidelines.

Occupational Risk Characterisation

Given the critical systemic long-term health effects, the chemical may pose an unreasonable risk to workers unless adequate control measures to minimise exposure to the chemical are implemented. The chemical should be appropriately classified and labelled to ensure that a person conducting a business or undertaking (PCBU) at a workplace (such as an employer) has adequate information to determine appropriate controls.

NICNAS Recommendation

Current risk management measures are considered adequate for the protection of public and workers’ health and safety, provided that all requirements are met under workplace health and safety and poisons legislation as adopted by the relevant state or territory. No further assessment is required.

Regulatory Control

Public Health

Current restrictions control the use of lead and lead compounds in cosmetics, paint, tinters, inks or ink additives, which effectively reduces the risk of public exposure to lead and lead compounds that have had historical use in cosmetics, for example, in face powders (Needham, 1976). The availability and permissible lead content in products, such as paint, are regulated in terms of availability and concentration (SUSMP, 2012). Products that historically contained lead or lead compounds, like the white pigment in paint, still pose an exposure risk to the public due to their existence in the public domain.

The National Health and Medical Research Council (NHMRC) of Australia has published recommendations regarding how the public can manage exposure to lead by mitigating the risk (NHMRC, 2009). Methods for the safe approach to painting a house (when there is a likelihood of lead paint having been used previously) have been published by the Department of Sustainability, Environment, Water, Population and Communities (DSEWPaC, 2009).

Work Health and Safety

The health risk to workers from these chemicals is controlled when correct classification and labelling are considered, and adequate control measures to minimise occupational exposure and protective clothing are implemented. Safe Work Australia (SWA) encourages working safely with lead and promotes the National Code of Practice for the Control and Safe Use of Inorganic Lead at Work [NOHSC: 2015 (1994)] and the National Standard for the Control of Inorganic Lead at Work [NOHSC:1012 (1994)]. These Codes of Practice, in addition to the Model Work Health and Safety Regulations, 2011 are available from the SWA website.
The chemicals are recommended for classification and labelling under the current Approved Criteria and adopted Globally Harmonized System (GHS) of Classification and Labelling of Chemicals as below. This does not consider classification of physical hazards and environmental hazards.

The classification proposed below is based on read across principles (see Grouping Rationale). It should be used as a default for all members of the group. If empirical data become available for any member of the group indicating that a lower (or higher) classification is appropriate for the specific chemical, this may be used to amend the default classification for the chemical.

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Approved Criteria (HSIS)a</th>
<th>GHS Classification (HCIS)b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Toxicity</td>
<td>Harmful by inhalation (Xn; R20)*</td>
<td>Harmful if inhaled - Cat. 4 (H332)</td>
</tr>
<tr>
<td>Repeat Dose Toxicity</td>
<td>Danger of cumulative effects (R33)*</td>
<td>May cause damage to organs through prolonged or repeated exposure - Cat. 2 (H373)</td>
</tr>
<tr>
<td>Genotoxicity</td>
<td>Muta. Cat 3 - Possible risk of irreversible effects (Xn; R68)</td>
<td>Suspected of causing genetic defects - Cat. 2 (H341)</td>
</tr>
<tr>
<td>Carcinogenicity</td>
<td>Carc. Cat 3 - Limited evidence of a carcinogenic effect (Xn; R40)</td>
<td>Suspected of causing cancer - Cat. 2 (H351)</td>
</tr>
<tr>
<td>Reproductive and Developmental Toxicity</td>
<td>Repro. Cat 1 - May cause harm to the unborn child (T; R61)* Repro. Cat 3 - Possible risk of impaired fertility (Xn; R62)*</td>
<td>May damage the unborn child. Suspected of damaging fertility - Repr. 1A (H360Df)</td>
</tr>
</tbody>
</table>

a Approved Criteria for Classifying Hazardous Substances [NOHSC:1008(2004)].


* Existing Hazard Classification. No change recommended to this classification

Advice for consumers

Products containing the chemical should be used according to label instructions.

Advice for industry

Control measures to minimise the risk from oral and inhalation exposure to the chemical should be implemented in accordance with the hierarchy of controls. Approaches to minimise risk include substitution, isolation and engineering controls. Measures required to eliminate or minimise risk arising from storing, handling and using a hazardous chemical depend on the physical form and the manner in which the chemical is used. Examples of control measures which may minimise the risk include, but are not limited to:

- using closed systems or isolating operations;
- using local exhaust ventilation to prevent the chemical from entering the breathing zone of any worker;
- health monitoring for any worker who is at risk of exposure to the chemical if valid techniques are available to monitor the effect on the worker’s health;
air monitoring to ensure control measures in place are working effectively and continue to do so;

minimising manual processes and work tasks through automating processes;

work procedures that minimise splashes and spills;

regularly cleaning equipment and work areas; and

using protective equipment that is designed, constructed, and operated to ensure that the worker does not come into contact with the chemical.

Guidance on managing risks from hazardous chemicals are provided in the *Managing Risks of Hazardous Chemicals in the Workplace—Code of Practice* available on the Safe Work Australia website.

Personal protective equipment should not solely be relied upon to control risk and should only be used when all other reasonably practicable control measures do not eliminate or sufficiently minimise risk. Guidance in selecting personal protective equipment can be obtained from Australian, Australian/New Zealand or other approved standards.

**Obligations under workplace health and safety legislation**

Information in this report should be taken into account to assist with meeting obligations under workplace health and safety legislation as adopted by the relevant state or territory. This includes, but is not limited to:

- ensuring that hazardous chemicals are correctly classified and labelled;

- ensuring that (material) safety data sheets ((m)SDS) containing accurate information about the hazards (relating to both health hazards and physicochemical (physical) hazards) of the chemical are prepared; and

- managing risks arising from storing, handling and using a hazardous chemical.

Your work health and safety regulator should be contacted for information on the work health and safety laws in your jurisdiction.

Information on how to prepare an (m)SDS and how to label containers of hazardous chemicals are provided in relevant codes of practice such as the *Preparation of Safety Data Sheets for Hazardous Chemicals— Code of Practice* and *Labelling of Workplace Hazardous Chemicals—Code of Practice*, respectively. These codes of practice are available from the Safe Work Australia website.

A review of the physical hazards of the chemical has not been undertaken as part of this assessment.

**References**


Last Update 12 September 2013

### Chemical Identities

<table>
<thead>
<tr>
<th>Chemical Name in the Inventory and Synonyms</th>
<th>Carbonic acid, lead(2+) salt (1:1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lead carbonate</td>
</tr>
<tr>
<td></td>
<td>Dibasic lead carbonate</td>
</tr>
<tr>
<td></td>
<td>Lead(2+) carbonate</td>
</tr>
<tr>
<td></td>
<td>Plumbous carbonate</td>
</tr>
<tr>
<td>CAS Number</td>
<td>598-63-0</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Structural Formula</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Molecular Formula</strong></td>
<td>CH₂O₃.Pb</td>
</tr>
<tr>
<td><strong>Molecular Weight</strong></td>
<td>267.21</td>
</tr>
</tbody>
</table>

| **Chemical Name in the Inventory and Synonyms** | Lead, bis(carbonato(2-))dihydroxytri-
Basic lead carbonate
Lead hydroxide carbonate
Carbonic acid, lead salt, basic
Lead subcarbonate
Lead, bis(carbonato)dihydroxytri- |
| **CAS Number** | 1319-46-6 |
| **Structural Formula** | |

<table>
<thead>
<tr>
<th>Molecular Formula</th>
<th>C₂H₂O₈Pb₃</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Weight</td>
<td>775.63</td>
</tr>
</tbody>
</table>